Symbols / EYPT $11.85 -5.20% EyePoint, Inc.
EYPT Chart
About
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 988.67M |
| Enterprise Value | 705.38M | Income | -231.96M | Sales | 31.37M |
| Book/sh | 3.70 | Cash/sh | 3.67 | Dividend Yield | — |
| Payout | 0.00% | Employees | 214 | IPO | — |
| P/E | — | Forward P/E | -4.32 | PEG | — |
| P/S | 31.52 | P/B | 3.21 | P/C | — |
| EV/EBITDA | -2.92 | EV/Sales | 22.48 | Quick Ratio | 8.29 |
| Current Ratio | 8.88 | Debt/Eq | 7.45 | LT Debt/Eq | — |
| EPS (ttm) | -3.17 | EPS next Y | -2.74 | EPS Growth | — |
| Revenue Growth | -94.70% | Earnings | 2026-05-06 | ROA | -38.89% |
| ROE | -72.19% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -113.46% | Profit Margin | 0.00% | Shs Outstand | 83.43M |
| Shs Float | 57.65M | Short Float | 17.33% | Short Ratio | 6.52 |
| Short Interest | — | 52W High | 19.11 | 52W Low | 3.91 |
| Beta | 1.79 | Avg Volume | 1.33M | Volume | 751.77K |
| Target Price | $37.42 | Recom | Strong_buy | Prev Close | $12.50 |
| Price | $11.85 | Change | -5.20% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-09 | main | Citigroup | Buy → Buy | $35 |
| 2026-03-05 | main | HC Wainwright & Co. | Buy → Buy | $30 |
| 2026-03-04 | main | Chardan Capital | Buy → Buy | $29 |
| 2025-11-06 | main | RBC Capital | Outperform → Outperform | $39 |
| 2025-08-07 | main | Chardan Capital | Buy → Buy | $27 |
| 2025-08-06 | main | HC Wainwright & Co. | Buy → Buy | $23 |
| 2025-06-17 | init | RBC Capital | — → Outperform | $28 |
| 2025-05-29 | reit | HC Wainwright & Co. | Buy → Buy | $22 |
| 2025-05-16 | main | Mizuho | Outperform → Outperform | $26 |
| 2025-05-08 | main | Chardan Capital | Buy → Buy | $27 |
| 2025-03-06 | main | Chardan Capital | Buy → Buy | $33 |
| 2025-03-06 | reit | HC Wainwright & Co. | Buy → Buy | $22 |
| 2025-02-06 | main | Chardan Capital | Buy → Buy | $33 |
| 2025-01-07 | init | Citigroup | — → Buy | $33 |
| 2024-12-05 | reit | HC Wainwright & Co. | Buy → Buy | $22 |
| 2024-11-11 | main | Baird | Outperform → Outperform | $33 |
| 2024-11-11 | main | HC Wainwright & Co. | Buy → Buy | $22 |
| 2024-11-08 | main | Chardan Capital | Buy → Buy | $33 |
| 2024-10-29 | main | Chardan Capital | Buy → Buy | $28 |
| 2024-10-25 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
- EyePoint Inc (EYPT) Stock Price Quote Today & Current Price Chart - Capital.com ue, 31 Mar 2026 02
- Discipline and Rules-Based Execution in EYPT Response - Stock Traders Daily Sun, 29 Mar 2026 19
- [SCHEDULE 13G/A] EyePoint, Inc. Amended Passive Investment Disclosure - Stock Titan hu, 26 Mar 2026 22
- $EYPT stock is down 13% today. Here's what we see in our data. - Quiver Quantitative hu, 05 Mar 2026 19
- EyePoint, Inc.'s (NASDAQ:EYPT) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors - simplywall.st Wed, 04 Feb 2026 08
- Despite currently being unprofitable, EyePoint (NASDAQ:EYPT) has delivered a 195% return to shareholders over 3 years - Yahoo Finance Mon, 02 Feb 2026 08
- EyePoint: The 'Pre-Readout' Surge Is Hiding A Commercial Reality Check (NASDAQ:EYPT) - Seeking Alpha hu, 05 Mar 2026 08
- Eyepoint Pharmaceuticals (NASDAQ:EYPT) Shares Down 9.1% - Here's Why - MarketBeat hu, 12 Mar 2026 07
- $EYPT stock is up 14% today. Here's what we see in our data. - Quiver Quantitative hu, 04 Dec 2025 08
- EyePoint piles up $306M to push eye disease drug through Phase 3 trials - Stock Titan Wed, 04 Mar 2026 08
- EyePoint (EYPT): Assessing Valuation After Earnings Upgrades and Strong Momentum-Driven Share Gains - Yahoo Finance ue, 23 Dec 2025 08
- A Look At EyePoint Pharmaceuticals (EYPT) Valuation Following Recent Mixed Share Price Performance - simplywall.st Wed, 18 Mar 2026 07
- EyePoint files a lawsuit against Ocular (EYPT:NASDAQ) - Seeking Alpha Sat, 21 Mar 2026 07
- [Form 4] EyePoint, Inc. Insider Trading Activity - Stock Titan ue, 24 Mar 2026 20
- EyePoint Pharmaceuticals (EYPT): Valuation Update Following Positive Phase 3 DURAVYU Safety Review - Yahoo Finance Wed, 19 Nov 2025 08
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
31.37
-27.50%
|
43.27
-5.97%
|
46.02
+11.14%
|
41.40
|
| Operating Revenue |
|
31.37
-27.50%
|
43.27
-5.97%
|
46.02
+11.14%
|
41.40
|
| Cost Of Revenue |
|
2.07
-44.34%
|
3.71
-19.86%
|
4.63
-44.37%
|
8.33
|
| Reconciled Cost Of Revenue |
|
2.07
-44.34%
|
3.71
-19.86%
|
4.63
-41.59%
|
7.93
|
| Gross Profit |
|
29.30
-25.92%
|
39.56
-4.41%
|
41.39
+25.12%
|
33.08
|
| Operating Expense |
|
272.74
+47.10%
|
185.41
+59.22%
|
116.45
+3.96%
|
112.02
|
| Research And Development |
|
221.04
+66.29%
|
132.93
+105.57%
|
64.66
+30.26%
|
49.64
|
| Selling General And Administration |
|
51.70
-1.50%
|
52.49
+1.35%
|
51.79
-14.15%
|
60.32
|
| Selling And Marketing Expense |
|
0.09
-31.30%
|
0.13
-98.88%
|
11.69
-54.17%
|
25.51
|
| General And Administrative Expense |
|
51.61
-1.43%
|
52.36
+30.56%
|
40.10
+15.18%
|
34.82
|
| Other Gand A |
|
51.61
-1.43%
|
52.36
+30.56%
|
40.10
+15.18%
|
34.82
|
| Total Expenses |
|
274.81
+45.30%
|
189.13
+56.19%
|
121.08
+0.62%
|
120.34
|
| Operating Income |
|
-243.43
-66.90%
|
-145.85
-94.30%
|
-75.07
+4.90%
|
-78.94
|
| Total Operating Income As Reported |
|
-243.43
-66.90%
|
-145.85
-94.30%
|
-75.07
+24.66%
|
-99.64
|
| EBITDA |
|
-229.34
-77.47%
|
-129.23
-87.28%
|
-69.00
+28.58%
|
-96.62
|
| Normalized EBITDA |
|
-229.34
-77.47%
|
-129.23
-91.01%
|
-67.65
+9.02%
|
-74.36
|
| Reconciled Depreciation |
|
2.31
+49.94%
|
1.54
+231.90%
|
0.46
-81.03%
|
2.45
|
| EBIT |
|
-231.65
-77.15%
|
-130.77
-88.25%
|
-69.47
+29.88%
|
-99.06
|
| Total Unusual Items |
|
0.00
|
0.00
+100.00%
|
-1.35
+93.95%
|
-22.26
|
| Total Unusual Items Excluding Goodwill |
|
0.00
|
0.00
+100.00%
|
-1.35
+93.95%
|
-22.26
|
| Special Income Charges |
|
0.00
|
0.00
+100.00%
|
-1.35
+93.95%
|
-22.26
|
| Other Special Charges |
|
—
|
—
|
1.35
-13.60%
|
1.56
|
| Impairment Of Capital Assets |
|
—
|
—
|
0.00
-100.00%
|
20.70
|
| Net Income |
|
-231.96
-77.25%
|
-130.87
-84.86%
|
-70.80
+30.77%
|
-102.25
|
| Pretax Income |
|
-231.68
-77.15%
|
-130.78
-84.95%
|
-70.71
+30.85%
|
-102.25
|
| Net Non Operating Interest Income Expense |
|
11.75
-22.04%
|
15.07
+164.36%
|
5.70
+638.94%
|
-1.06
|
| Interest Expense Non Operating |
|
0.03
+135.71%
|
0.01
-98.88%
|
1.25
-60.90%
|
3.19
|
| Net Interest Income |
|
11.75
-22.04%
|
15.07
+164.36%
|
5.70
+638.94%
|
-1.06
|
| Interest Expense |
|
0.03
+135.71%
|
0.01
-98.88%
|
1.25
-60.90%
|
3.19
|
| Interest Income Non Operating |
|
11.78
-21.90%
|
15.09
+117.12%
|
6.95
+226.09%
|
2.13
|
| Interest Income |
|
11.78
-21.90%
|
15.09
+117.12%
|
6.95
+226.09%
|
2.13
|
| Other Income Expense |
|
—
|
—
|
-1.35
+93.95%
|
-22.26
|
| Tax Provision |
|
0.28
+210.00%
|
0.09
+8.43%
|
0.08
|
0.00
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
+100.00%
|
-0.28
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-231.96
-77.25%
|
-130.87
-84.86%
|
-70.80
+30.77%
|
-102.25
|
| Net Income From Continuing Operation Net Minority Interest |
|
-231.96
-77.25%
|
-130.87
-84.86%
|
-70.80
+30.77%
|
-102.25
|
| Net Income From Continuing And Discontinued Operation |
|
-231.96
-77.25%
|
-130.87
-84.86%
|
-70.80
+30.77%
|
-102.25
|
| Net Income Continuous Operations |
|
-231.96
-77.25%
|
-130.87
-84.86%
|
-70.80
+30.77%
|
-102.25
|
| Normalized Income |
|
-231.96
-77.25%
|
-130.87
-87.68%
|
-69.73
+12.83%
|
-80.00
|
| Net Income Common Stockholders |
|
-231.96
-77.25%
|
-130.87
-84.86%
|
-70.80
+30.77%
|
-102.25
|
| Diluted EPS |
|
-3.17
-36.64%
|
-2.32
-27.47%
|
-1.82
+33.58%
|
-2.74
|
| Basic EPS |
|
-3.17
-36.64%
|
-2.32
-27.47%
|
-1.82
+33.58%
|
-2.74
|
| Basic Average Shares |
|
73.25
+30.11%
|
56.30
+44.71%
|
38.90
+4.25%
|
37.32
|
| Diluted Average Shares |
|
73.25
+30.11%
|
56.30
+44.71%
|
38.90
+4.25%
|
37.32
|
| Diluted NI Availto Com Stockholders |
|
-231.96
-77.25%
|
-130.87
-84.86%
|
-70.80
+30.77%
|
-102.25
|
| Amortization |
|
—
|
—
|
0.00
-100.00%
|
2.05
|
| Amortization Of Intangibles Income Statement |
|
—
|
—
|
0.00
-100.00%
|
2.05
|
| Depreciation Amortization Depletion Income Statement |
|
—
|
—
|
0.00
-100.00%
|
2.05
|
| Depreciation And Amortization In Income Statement |
|
—
|
—
|
0.00
-100.00%
|
2.05
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
364.00
-13.02%
|
418.46
+17.82%
|
355.18
+96.93%
|
180.36
|
| Current Assets |
|
328.65
-14.26%
|
383.31
+11.17%
|
344.80
+99.53%
|
172.81
|
| Cash Cash Equivalents And Short Term Investments |
|
306.09
-17.48%
|
370.91
+12.04%
|
331.05
+129.00%
|
144.56
|
| Cash And Cash Equivalents |
|
101.82
+2.12%
|
99.70
-64.55%
|
281.26
+194.11%
|
95.63
|
| Other Short Term Investments |
|
204.26
-24.68%
|
271.21
+444.74%
|
49.79
+1.76%
|
48.93
|
| Receivables |
|
0.65
+7.25%
|
0.61
-24.60%
|
0.81
-94.81%
|
15.50
|
| Accounts Receivable |
|
0.65
+7.25%
|
0.61
-24.60%
|
0.81
-94.81%
|
15.50
|
| Inventory |
|
1.81
-21.34%
|
2.31
-40.99%
|
3.91
+35.34%
|
2.89
|
| Raw Materials |
|
1.23
-25.83%
|
1.66
+27.17%
|
1.30
-7.59%
|
1.41
|
| Work In Process |
|
0.58
-9.88%
|
0.65
-26.53%
|
0.88
-18.18%
|
1.08
|
| Finished Goods |
|
—
|
0.00
-100.00%
|
1.72
+332.41%
|
0.40
|
| Prepaid Assets |
|
18.14
+124.63%
|
8.08
+0.57%
|
8.03
-11.52%
|
9.08
|
| Other Current Assets |
|
1.96
+39.79%
|
1.41
+39.25%
|
1.01
+29.03%
|
0.78
|
| Total Non Current Assets |
|
35.34
+0.52%
|
35.16
+238.59%
|
10.38
+37.57%
|
7.55
|
| Net PPE |
|
29.25
+0.24%
|
29.18
+185.10%
|
10.23
+38.33%
|
7.40
|
| Gross PPE |
|
35.26
+6.11%
|
33.23
+159.54%
|
12.80
+34.72%
|
9.51
|
| Accumulated Depreciation |
|
-6.02
-48.31%
|
-4.06
-57.80%
|
-2.57
-22.02%
|
-2.11
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Construction In Progress |
|
1.46
-3.12%
|
1.51
-59.58%
|
3.73
|
0.00
|
| Other Properties |
|
29.62
+7.33%
|
27.60
+242.04%
|
8.07
-5.04%
|
8.50
|
| Leases |
|
4.18
+1.26%
|
4.13
+309.52%
|
1.01
+0.00%
|
1.01
|
| Goodwill And Other Intangible Assets |
|
—
|
—
|
—
|
0.00
|
| Other Intangible Assets |
|
—
|
—
|
—
|
—
|
| Other Non Current Assets |
|
6.09
+1.89%
|
5.98
+3888.00%
|
0.15
+0.00%
|
0.15
|
| Total Liabilities Net Minority Interest |
|
57.88
-29.38%
|
81.96
-7.76%
|
88.86
+5.80%
|
83.99
|
| Current Liabilities |
|
37.02
-24.51%
|
49.05
-22.47%
|
63.26
+83.17%
|
34.54
|
| Payables And Accrued Expenses |
|
20.35
+13.09%
|
17.99
+57.93%
|
11.39
-10.73%
|
12.76
|
| Payables |
|
10.49
-10.50%
|
11.72
+80.21%
|
6.50
+9.88%
|
5.92
|
| Accounts Payable |
|
10.49
-10.50%
|
11.72
+80.21%
|
6.50
+9.88%
|
5.92
|
| Current Accrued Expenses |
|
9.86
+57.18%
|
6.27
+28.28%
|
4.89
-28.55%
|
6.84
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
14.53
+22.86%
|
11.83
-6.34%
|
12.63
+32.75%
|
9.52
|
| Current Debt And Capital Lease Obligation |
|
—
|
—
|
—
|
10.47
|
| Current Debt |
|
—
|
—
|
—
|
10.47
|
| Current Capital Lease Obligation |
|
—
|
—
|
—
|
0.58
|
| Current Deferred Liabilities |
|
0.00
-100.00%
|
17.78
-53.92%
|
38.59
+3102.66%
|
1.21
|
| Current Deferred Revenue |
|
0.00
-100.00%
|
17.78
-53.92%
|
38.59
+3102.66%
|
1.21
|
| Other Current Liabilities |
|
2.14
+48.61%
|
1.44
+122.91%
|
0.65
+11.57%
|
0.58
|
| Total Non Current Liabilities Net Minority Interest |
|
20.86
-36.63%
|
32.92
+28.59%
|
25.60
-48.24%
|
49.45
|
| Long Term Debt And Capital Lease Obligation |
|
20.77
-4.97%
|
21.86
+345.54%
|
4.91
-86.10%
|
35.29
|
| Long Term Debt |
|
—
|
—
|
—
|
29.31
|
| Long Term Capital Lease Obligation |
|
20.77
-4.97%
|
21.86
+345.54%
|
4.91
-18.01%
|
5.98
|
| Non Current Deferred Liabilities |
|
0.00
-100.00%
|
10.85
-47.55%
|
20.69
+52.63%
|
13.56
|
| Non Current Deferred Revenue |
|
0.00
-100.00%
|
10.85
-47.55%
|
20.69
+52.63%
|
13.56
|
| Other Non Current Liabilities |
|
0.09
-57.56%
|
0.20
|
—
|
0.60
|
| Stockholders Equity |
|
306.11
-9.03%
|
336.50
+26.35%
|
266.32
+176.36%
|
96.37
|
| Common Stock Equity |
|
306.11
-9.03%
|
336.50
+26.35%
|
266.32
+176.36%
|
96.37
|
| Capital Stock |
|
0.08
+22.06%
|
0.07
+38.78%
|
0.05
+44.12%
|
0.03
|
| Common Stock |
|
0.08
+22.06%
|
0.07
+38.78%
|
0.05
+44.12%
|
0.03
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
82.83
+21.33%
|
68.27
+39.20%
|
49.04
+43.89%
|
34.08
|
| Ordinary Shares Number |
|
82.83
+21.33%
|
68.27
+39.20%
|
49.04
+43.89%
|
34.08
|
| Additional Paid In Capital |
|
1,410.05
+16.69%
|
1,208.42
+19.94%
|
1,007.56
+31.38%
|
766.90
|
| Retained Earnings |
|
-1,104.98
-26.57%
|
-873.02
-17.63%
|
-742.15
-10.55%
|
-671.35
|
| Gains Losses Not Affecting Retained Earnings |
|
0.96
-6.52%
|
1.03
+18.98%
|
0.86
+9.92%
|
0.79
|
| Other Equity Adjustments |
|
0.96
-6.52%
|
1.03
+18.98%
|
0.86
+9.92%
|
0.79
|
| Total Equity Gross Minority Interest |
|
306.11
-9.03%
|
336.50
+26.35%
|
266.32
+176.36%
|
96.37
|
| Total Capitalization |
|
306.11
-9.03%
|
336.50
+26.35%
|
266.32
+111.91%
|
125.68
|
| Working Capital |
|
291.63
-12.75%
|
334.26
+18.73%
|
281.54
+103.61%
|
138.27
|
| Invested Capital |
|
306.11
-9.03%
|
336.50
+26.35%
|
266.32
+95.61%
|
136.15
|
| Total Debt |
|
20.77
-4.97%
|
21.86
+345.54%
|
4.91
-89.28%
|
45.77
|
| Capital Lease Obligations |
|
20.77
-4.97%
|
21.86
+345.54%
|
4.91
-18.01%
|
5.98
|
| Net Tangible Assets |
|
306.11
-9.03%
|
336.50
+26.35%
|
266.32
+176.36%
|
96.37
|
| Tangible Book Value |
|
306.11
-9.03%
|
336.50
+26.35%
|
266.32
+176.36%
|
96.37
|
| Line Of Credit |
|
—
|
—
|
0.00
-100.00%
|
10.47
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-240.11
-90.22%
|
-126.23
-6832.05%
|
1.88
+102.88%
|
-65.00
|
| Cash Flow From Continuing Operating Activities |
|
-240.11
-90.22%
|
-126.23
-6832.05%
|
1.88
+102.88%
|
-65.00
|
| Net Income From Continuing Operations |
|
-231.96
-77.25%
|
-130.87
-84.86%
|
-70.80
+30.77%
|
-102.25
|
| Depreciation Amortization Depletion |
|
2.31
+49.94%
|
1.54
+231.90%
|
0.46
-81.03%
|
2.45
|
| Depreciation |
|
2.31
+49.94%
|
1.54
+231.90%
|
0.46
+17.17%
|
0.40
|
| Amortization Cash Flow |
|
—
|
—
|
0.00
-100.00%
|
2.05
|
| Depreciation And Amortization |
|
2.31
+49.94%
|
1.54
+231.90%
|
0.46
-81.03%
|
2.45
|
| Amortization Of Intangibles |
|
—
|
—
|
0.00
-100.00%
|
2.05
|
| Other Non Cash Items |
|
-4.83
+18.90%
|
-5.95
-595.44%
|
-0.86
-53.41%
|
-0.56
|
| Stock Based Compensation |
|
27.87
-24.13%
|
36.74
+204.72%
|
12.06
-14.95%
|
14.18
|
| Provisionand Write Offof Assets |
|
—
|
0.00
-100.00%
|
0.69
-64.44%
|
1.95
|
| Asset Impairment Charge |
|
—
|
—
|
0.00
-100.00%
|
20.70
|
| Deferred Tax |
|
0.28
+210.00%
|
0.09
+8.43%
|
0.08
|
0.00
|
| Deferred Income Tax |
|
0.28
+210.00%
|
0.09
+8.43%
|
0.08
|
0.00
|
| Operating Gains Losses |
|
—
|
—
|
1.35
-13.60%
|
1.56
|
| Change In Working Capital |
|
-33.78
-21.63%
|
-27.77
-147.17%
|
58.88
+2047.80%
|
-3.02
|
| Change In Receivables |
|
-10.67
-4271.72%
|
-0.24
-101.69%
|
14.43
+642.15%
|
-2.66
|
| Changes In Account Receivables |
|
-10.67
-4271.72%
|
-0.24
-101.69%
|
14.43
+642.15%
|
-2.66
|
| Change In Inventory |
|
0.49
-69.25%
|
1.60
+203.03%
|
-1.55
-104.34%
|
-0.76
|
| Change In Payables And Accrued Expense |
|
4.68
-18.39%
|
5.73
+277.29%
|
1.52
+26.79%
|
1.20
|
| Change In Other Working Capital |
|
-28.17
+2.96%
|
-29.03
-165.25%
|
44.48
+5667.46%
|
-0.80
|
| Change In Other Current Assets |
|
-0.11
+98.06%
|
-5.83
|
0.00
|
—
|
| Investing Cash Flow |
|
68.58
+131.26%
|
-219.35
-6517.04%
|
-3.31
+80.80%
|
-17.27
|
| Cash Flow From Continuing Investing Activities |
|
68.58
+131.26%
|
-219.35
-6517.04%
|
-3.31
+80.80%
|
-17.27
|
| Net PPE Purchase And Sale |
|
-3.12
+22.88%
|
-4.05
-16.34%
|
-3.48
-62.00%
|
-2.15
|
| Purchase Of PPE |
|
-3.28
+19.05%
|
-4.05
-16.34%
|
-3.48
-62.00%
|
-2.15
|
| Sale Of PPE |
|
0.15
|
0.00
|
—
|
—
|
| Capital Expenditure |
|
-3.28
+19.05%
|
-4.05
-16.34%
|
-3.48
-62.00%
|
-2.15
|
| Net Investment Purchase And Sale |
|
71.70
+133.30%
|
-215.30
-128256.55%
|
0.17
+101.11%
|
-15.12
|
| Purchase Of Investment |
|
-252.02
+36.73%
|
-398.30
-622.66%
|
-55.12
+60.38%
|
-139.12
|
| Sale Of Investment |
|
323.73
+76.90%
|
183.00
+231.02%
|
55.28
-55.42%
|
124.00
|
| Financing Cash Flow |
|
173.65
+5.87%
|
164.02
-12.32%
|
187.07
+27211.59%
|
-0.69
|
| Cash Flow From Continuing Financing Activities |
|
173.65
+5.87%
|
164.02
-12.32%
|
187.07
+27211.59%
|
-0.69
|
| Net Issuance Payments Of Debt |
|
-0.10
+0.00%
|
-0.10
+99.74%
|
-40.51
-2026.34%
|
2.10
|
| Issuance Of Debt |
|
—
|
0.00
-100.00%
|
5.30
-92.83%
|
73.88
|
| Repayment Of Debt |
|
-0.10
+0.00%
|
-0.10
+99.77%
|
-45.81
+36.17%
|
-71.77
|
| Long Term Debt Issuance |
|
—
|
0.00
-100.00%
|
5.30
-92.83%
|
73.88
|
| Long Term Debt Payments |
|
-0.10
+0.00%
|
-0.10
+99.77%
|
-45.81
+36.17%
|
-71.77
|
| Net Long Term Debt Issuance |
|
-0.10
+0.00%
|
-0.10
+99.74%
|
-40.51
-2026.34%
|
2.10
|
| Short Term Debt Issuance |
|
—
|
—
|
5.30
-87.92%
|
43.88
|
| Short Term Debt Payments |
|
—
|
—
|
-15.78
+52.77%
|
-33.40
|
| Net Short Term Debt Issuance |
|
—
|
—
|
-10.47
-200.00%
|
10.47
|
| Net Common Stock Issuance |
|
173.44
+6.20%
|
163.31
-27.79%
|
226.17
|
0.00
|
| Proceeds From Stock Option Exercised |
|
2.24
-62.68%
|
6.00
+77.58%
|
3.38
+754.94%
|
0.40
|
| Net Other Financing Charges |
|
-1.93
+62.75%
|
-5.18
-163.15%
|
-1.97
+38.21%
|
-3.19
|
| Changes In Cash |
|
2.12
+101.17%
|
-181.56
-197.81%
|
185.63
+323.76%
|
-82.96
|
| Effect Of Exchange Rate Changes |
|
—
|
—
|
—
|
—
|
| Beginning Cash Position |
|
99.85
-64.52%
|
281.41
+193.80%
|
95.78
-46.41%
|
178.74
|
| End Cash Position |
|
101.97
+2.12%
|
99.85
-64.52%
|
281.41
+193.80%
|
95.78
|
| Free Cash Flow |
|
-243.39
-86.82%
|
-130.28
-8001.87%
|
-1.61
+97.61%
|
-67.16
|
| Interest Paid Supplemental Data |
|
—
|
0.00
-100.00%
|
1.41
-45.96%
|
2.60
|
| Income Tax Paid Supplemental Data |
|
—
|
—
|
—
|
0.60
|
| Common Stock Issuance |
|
173.44
+6.20%
|
163.31
-27.79%
|
226.17
|
0.00
|
| Issuance Of Capital Stock |
|
173.44
+6.20%
|
163.31
-27.79%
|
226.17
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-03-24 View
- 8-K2026-03-20 View
- 42026-03-16 View
- 42026-03-06 View
- 10-K2026-03-05 View
- 42026-03-05 View
- 8-K2026-03-04 View
- 8-K2026-03-02 View
- 42026-02-18 View
- 42026-01-07 View
- 42026-01-07 View
- 42026-01-07 View
- 42026-01-07 View
- 8-K2026-01-07 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|